300 related articles for article (PubMed ID: 26819957)
1. Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines.
Phua KK
J Immunol Res; 2015; 2015():680620. PubMed ID: 26819957
[TBL] [Abstract][Full Text] [Related]
2. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
3. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.
Saluja SS; Hanlon DJ; Sharp FA; Hong E; Khalil D; Robinson E; Tigelaar R; Fahmy TM; Edelson RL
Int J Nanomedicine; 2014; 9():5231-46. PubMed ID: 25419128
[TBL] [Abstract][Full Text] [Related]
4. RNA-Based Vaccines in Cancer Immunotherapy.
McNamara MA; Nair SK; Holl EK
J Immunol Res; 2015; 2015():794528. PubMed ID: 26665011
[TBL] [Abstract][Full Text] [Related]
5. Messenger RNA (mRNA) nanoparticle tumour vaccination.
Phua KK; Nair SK; Leong KW
Nanoscale; 2014 Jul; 6(14):7715-29. PubMed ID: 24904987
[TBL] [Abstract][Full Text] [Related]
6. Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.
Diken M; Kreiter S; Selmi A; Türeci O; Sahin U
Methods Mol Biol; 2013; 969():235-46. PubMed ID: 23296938
[TBL] [Abstract][Full Text] [Related]
7. Advances in dendritic cell-based vaccine of cancer.
Zhang X; Gordon JR; Xiang J
Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664
[TBL] [Abstract][Full Text] [Related]
8. Truncated TERT mRNA transfected dendritic cells evoke TERT specific antitumor response in vivo.
Qiu J; Lil GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W; Song HP
Hepatogastroenterology; 2007; 54(75):681-7. PubMed ID: 17591041
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination.
Ben-Akiva E; Karlsson J; Hemmati S; Yu H; Tzeng SY; Pardoll DM; Green JJ
Proc Natl Acad Sci U S A; 2023 Jun; 120(26):e2301606120. PubMed ID: 37339211
[TBL] [Abstract][Full Text] [Related]
10. Challenges and advances towards the rational design of mRNA vaccines.
Pollard C; De Koker S; Saelens X; Vanham G; Grooten J
Trends Mol Med; 2013 Dec; 19(12):705-13. PubMed ID: 24138818
[TBL] [Abstract][Full Text] [Related]
11. Enhancing tumor specific immune responses by transcutaneous vaccination.
Saliba H; Heurtault B; Bouharoun-Tayoun H; Flacher V; Frisch B; Fournel S; Chamat S
Expert Rev Vaccines; 2017 Nov; 16(11):1079-1094. PubMed ID: 28937293
[TBL] [Abstract][Full Text] [Related]
12. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
13. Tumor vaccination using messenger RNA: prospects of a future therapy.
Kreiter S; Diken M; Selmi A; Türeci Ö; Sahin U
Curr Opin Immunol; 2011 Jun; 23(3):399-406. PubMed ID: 21497074
[TBL] [Abstract][Full Text] [Related]
14. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy.
Amoozgar Z; Goldberg MS
Adv Drug Deliv Rev; 2015 Aug; 91():38-51. PubMed ID: 25280471
[TBL] [Abstract][Full Text] [Related]
15. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.
Michiels A; Tuyaerts S; Bonehill A; Heirman C; Corthals J; Thielemans K
Methods Mol Biol; 2008; 423():155-63. PubMed ID: 18370196
[TBL] [Abstract][Full Text] [Related]
16. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
[TBL] [Abstract][Full Text] [Related]
17. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
18. Antigen-Loaded Upconversion Nanoparticles for Dendritic Cell Stimulation, Tracking, and Vaccination in Dendritic Cell-Based Immunotherapy.
Xiang J; Xu L; Gong H; Zhu W; Wang C; Xu J; Feng L; Cheng L; Peng R; Liu Z
ACS Nano; 2015 Jun; 9(6):6401-11. PubMed ID: 26028363
[TBL] [Abstract][Full Text] [Related]
19. Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.
Roeven MW; Hobo W; van der Voort R; Fredrix H; Norde WJ; Teijgeler K; Ruiters MH; Schaap N; Dolstra H
J Immunother; 2015 May; 38(4):145-54. PubMed ID: 25839440
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor antigens to dendritic cells using particulate carriers.
Joshi MD; Unger WJ; Storm G; van Kooyk Y; Mastrobattista E
J Control Release; 2012 Jul; 161(1):25-37. PubMed ID: 22580109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
